Vertex Pharmaceuticals Incorporated (VRTX) Stock Score, Valuation & Financial Research
Vertex Pharmaceuticals Incorporated is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 42/100.
Quick answer for VRTX
Vertex Pharmaceuticals Incorporated currently has a Wall Street Score of 42/100. The stored market price is $515.44. Its financial score is 38/100. Its valuation score is 10/100. These figures are a research snapshot, not a buy or sell recommendation.
What Vertex Pharmaceuticals Incorporated does
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabete
VRTX financial snapshot
- Wall Street Score:
- 42/100
- Current price:
- $515.44
- Market capitalization:
- $130.82B
- Revenue:
- $12.26B
- Net income:
- $4.34B
- Free cash flow:
- $3.19B
- Cash:
- $5.49B
- Total debt:
- $1.99B
- EPS:
- 15.46
- P/E ratio:
- 33.3x
- Financial score:
- 38/100
- Valuation score:
- 10/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $3.19B, showing positive cash generation.
- The balance sheet shows $5.49B of cash versus $1.99B of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 38/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VRTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.